Cerus Corporation
2550 Stanwell Drive
Concord
California
94520
United States
Tel: 925-288-6000
Website: http://www.cerus.com/
446 articles about Cerus Corporation
-
Cerus Corporation Announces Preliminary Fourth Quarter and Full Year 2020 Product Revenue
1/11/2021
Cerus Corporation (Nasdaq: CERS) announced today preliminary product revenue for the fourth quarter and full year 2020 and provided 2021 product revenue guidance. Cerus’ unaudited preliminary product revenue for the fourth quarter of 2020 totaled $28.2 million, an increase of 35% over the $20.9 million recognized during the same period in the prior year.
-
Cerus’ Distribution Partner, CEI, Announces Three-Year Tender Award with the Minas Gerais Hematology and Hemotherapy Center Foundation (HemoMinas) in Brazil for the INTERCEPT Blood System for Platelets
12/15/2020
Cerus Corporation (Nasdaq: CERS) today announced that its distribution partner, Companhia Energética Integrada (CEI), was awarded a three-year contract with the HemoMinas Foundation (“HemoMinas”) of Brazil for the INTERCEPT Blood System for platelets. HemoMinas provides services and blood products in the state of Minas Gerais, and the Hemocentro of Belo Horizonte – the largest blood service of HemoMinas – distributes app
-
Cerus Corporation to Participate in Upcoming Virtual Investor Conferences - Nov 12, 2020
11/12/2020
Cerus Corporation announced that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, and Kevin D. Green, Cerus’ chief financial officer, are scheduled to participate in two conferences:.
-
Cerus Corporation Announces Record Third Quarter 2020 Results
10/29/2020
Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2020. Recent developments and highlights include: Q3 2020 Total Revenue of $29.2 million - driven by significant year-over-year platelet kit sales growth in the U.S. as well as plasma and platelet kit sales from the EMEA region. Total revenue was composed of (in millions, except %) :
-
Cerus Corporation to Release Third Quarter 2020 Financial Results on October 29, 2020
10/19/2020
Cerus Corporation (Nasdaq:CERS) announced today that its third quarter 2020 financial results will be released on Thursday, October 29, 2020, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook. To listen to the live webcast and
-
Cerus Corporation Announces Five-Year FDA Contract for the Development of Next Generation Pathogen Reduction Technology to Treat Whole Blood
10/13/2020
Cerus Corporation (Nasdaq:CERS) announced today it was awarded a five-year contract with the U.S. Food and Drug Administration (FDA) for the development of next-generation compounds to optimize pathogen reduction (PR) treatment of whole blood to reduce the risk of transfusion-transmitted infections. The contract value totals $11.1 million. This research is consistent with the FDA’s strategy for developing proactive, foun
-
Cerus Corporation to Participate in Upcoming Virtual Investor Conferences
9/9/2020
Cerus Corporation (Nasdaq:CERS) announced today that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, and Kevin D. Green, Cerus’ chief financial officer, are scheduled to participate in the following two conferences: The Cantor Fitzgerald Virtual Global Healthcare Conference on Tuesday, September 15 th at 2:00 P.M. ET. The H.C. Wainwright 22 nd Annual Global Investment Conference on
-
Cerus INTERCEPT Blood System Kit Shipments Surpass 7.5 Million Treatable Platelet and Plasma Doses Since Launch
8/7/2020
Cerus Corporation (Nasdaq:CERS) announced today that INTERCEPT Blood Systems disposable kit shipments have surpassed 7.5 million treatable platelet and plasma doses globally since commercial launch. “This is a significant milestone for Cerus and highlights the scope our technology has had within the transfusion industry and on the millions of patients worldwide transfused with INTERCEPT treated platelet and plasma co
-
Cerus Corporation Announces a Five-Year Tender Award by the Hong Kong Red Cross Blood Transfusion Service for INTERCEPT Blood Systems
7/30/2020
Cerus Corporation (Nasdaq:CERS) today announced it has been awarded a five-year tender by the Hong Kong Red Cross Blood Transfusion Services (BTS) for INTERCEPT Blood System for platelets. The Hong Kong Red Cross BTS is the only public institution providing blood to all hospitals, public and private, in Hong Kong. “Following a thorough selection process, we are pleased to be selected by the Hong Kong Red Cross BTS t
-
Cerus Corporation to Release Second Quarter 2020 Financial Results on August 4, 2020
7/23/2020
Cerus Corporation (Nasdaq:CERS) announced today that its second quarter 2020 financial results will be released on Tuesday, August 4, 2020, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook. To listen to the live webcast and vi
-
Cerus Corporation Reports Successful Inactivation of SARS-CoV-2 with the INTERCEPT Blood System for Plasma
7/7/2020
Cerus Corporation (Nasdaq:CERS) announced today study results demonstrating that the INTERCEPT Blood System inactivates SARS-CoV-2, the causative agent for COVID-19, in plasma components intended for transfusion. These data are consistent with prior INTERCEPT studies showing complete inactivation, to below the limit of detection, of other coronaviruses associated with severe pulmonary disease: MERS-CoV 1,2 (2018, 2019) a
-
Cerus Corporation Celebrates World Blood Donor Day
6/12/2020
Cerus Corporation (Nasdaq:CERS) celebrates World Blood Donor Day this Sunday, June 14, 2020. Enacted by the World Health Organization (WHO), World Blood Donor Day highlights the need for safe blood and safe blood products, while recognizing donors for their life-saving donations. This year’s “Safe blood saves lives” campaign calls attention to the
-
Cerus Corporation Announces FDA PMA Supplement Submission for Pathogen-Reduced Cryoprecipitated Fibrinogen Complex
5/26/2020
Cerus Corporation (Nasdaq:CERS) announced today that the Company has submitted a pre-market approval supplement (PMA-S) to the FDA for a pathogen reduced cryoprecipitated fibrinogen complex with 5-day post thaw storage. This product was previously granted FDA breakthrough device designation based on the potential to improve treatment of mass
-
Cerus Corporation Announces First Quarter 2020 Results
5/5/2020
Cerus Corporation announced financial results for the first quarter ended March 31, 2020.
-
Cerus Corporation Announces FDA Approval for INTERCEPT Blood System for Plasma with Alternate Plastic Disposable Kits
5/4/2020
Cerus Corporation (Nasdaq:CERS) announced today FDA regulatory approval for manufacture of INTERCEPT plasma with a new, alternative plastic disposable kit. The planned conversion to these new kits is part of the Company’s ongoing strategy to enhance its global supply chain integrity that was initiated several years ago. “The FDA approval for the new INTERCEPT plasma kit is significant as it is a prerequisite for our p
-
CERUS Announces the Acquisition of Laboratori Derivati Organici SpA (LDO) by Opocrin SpA
4/29/2020
- Transaction enables Opocrin to become a leading global producer of active biologics including heparin and heparinoids -
-
Cerus Corporation to Release First Quarter 2020 Financial Results on May 5, 2020
4/24/2020
Cerus Corporation (Nasdaq:CERS) announced today that its first quarter 2020 financial results will be released on Tuesday, May 5, 2020, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook. To access the live webcast, please visi
-
Cerus Corporation Announces Expansion of BARDA Funding to Support Development of INTERCEPT Blood System for Red Blood Cells
4/20/2020
Cerus Corporation (Nasdaq:CERS) today announced an amendment to the Company’s contract with the Biomedical Advanced Research and Development Authority (BARDA
-
Cerus Corporation Provides Update on COVID-19 Related Activities
4/6/2020
Cerus Corporation (Nasdaq:CERS) today announced the Company’s recent activities related to COVID-19 and efforts to ensure that patients have readily available access to pathogen-reduced blood components, including convalescent plasma. “As the world endures the impact from the current COVID-19 pandemic, our focused mission of ensuring the availability and safety of the world’s blood supply has never been more relevan
-
University Hospital Basel, Switzerland Transfuses First Two COVID-19 Patients With INTERCEPT Treated Coronavirus Convalescent Plasma
4/2/2020
Cerus Corporation announced that the University Hospital Basel transfused the first two COVID-19 patients with INTERCEPT treated coronavirus convalescent plasma.